Human African trypanosomiasis: Potential therapeutic benefits of an alternative suramin and melarsoprol regimen

Parasitology International

Volumn 51, Issue 4, 2002, Pages 381-388

  Jennings, Frank W ^a   Rodgers, Jean ^a   Bradley, Barbara ^a   Gettinby, George ^b   Kennedy, Peter G E ^c   Murray, Max ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c SOUTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Combination chemotherapy; Human African trypanosomiasis; Melarsoprol; Mouse model; Suramin

Indexed keywords

MELARSOPROL; SURAMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CENTRAL NERVOUS SYSTEM INFECTION; CONTROLLED STUDY; DRUG POTENTIATION; EXPERIMENTAL INFECTION; FEMALE; HUMAN; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RELAPSE; TREATMENT OUTCOME; TRYPANOSOMIASIS;

ANIMALS; ANTI-INFECTIVE AGENTS, LOCAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MELARSOPROL; MICE; PARASITEMIA; SURAMIN; TIME FACTORS; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMIASIS, AFRICAN;

MURINAE;

EID: 0036888193     PISSN: 13835769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1383-5769(02)00044-2     Document Type: Article

References (26)

1. Ross C.A., Sutherland D.V. Drug resistance in trypanosomatids. Hide G., Mottram J.C., Coombs G.H., Holmes P.H., Trypanosomiasis and leishmaniasis. Biology and control. 1997;259-269 CAB International, Oxford.
2. Apted F.I.C. Treatment of human trypanosomiasis. Mulligan H.W., The African trypanosomiasis. 1970;684-710 George Allen & Unwin, London.
3. Croft S.L., Urbina J.A., Brun R. Chemotherapy of human leishmaniasis and trypanosomiasis. Hide G., Mottram J.C., Coombs G.H., Holmes P.H., Trypanosomiasis and leishmaniasis; biology and control. 1997;245-257 CAB International, Oxford.
4. Hunter C.A., Kennedy P.G. Immunopathology in central nervous system human African trypanosomiasis. J. Neuroimmunol. 36:1992;91-95.
5. Jennings F.W., McNeil P.E., Ndung'u J.M., Murray M. Trypanosomiasis and encephalitis: possible aetiology and treatment. Trans. R. Soc. Trop. Med. Hyg. 83:1989;518-519.
6. Pepin J., Milord F. African trypanosomiasis and drug-induced encephalopathy: risk factors and pathogenesis. Trans. R. Soc. Trop. Med. Hyg. 85:1991;222-224.
7. Hurst E.W. The lesions produced in the central nervous system by certain organic arsenical compounds. J. Pathol. Bacteriol. 77:1959;523-534.
8. Lambert P.H., Berney M., Kazyumba G. Immune complexes in serum and in cerebrospinal fluid in African trypanosomiasis. Correlation with polyclonal B cell activation and with intracerebral immunoglobulin synthesis. J. Clin. Invest. 67:1981;77-85.
9. Poltera A.A. Immunopathological and chemotherapeutic studies in experimental trypanosomiasis with special reference to the heart and brain. Trans. R. Soc. Trop. Med. Hyg. 74:1980;706-715.
10. WHO. Control and surveillance of African trypanosomiasis. WHO technical report series, Geneva 1998;881:1-113.
11. Friedheim E.A.H. Mel B in the treatment of human trypanosomiasis. Am. J. Trop. Med. Hyg. 29:1949;173-180.
12. Friedheim E.A.H. Mel B in the treatment of tryparsamide resistant T. gambiense sleeping sickness: observations on drug resistance in the trypanosomes of the French Cameroun. Am. J. Trop. Med. 31:1951;218-235.
13. Friedheim E., Distefano D. Melarsoprol in the treatment of African sleeping sickness. ISCTRC (Mombasa). 1989;245-252.
14. Burri C., Nkunku S., Merolle A., et al. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet. 355:2000;1419-1425.
15. Pepin J., Milord F. The treatment of human African trypanosomiasis. Adv. Parasitol. 33:1994;1-47.
16. Gill AA. Why Africa is losing it's fight against disease. The Sunday Times Magazine 2000 September 17;17-22.
17. Atouguia J.M., Jennings F.W., Murray M. Successful treatment of experimental murine Trypanosoma brucei infection with topical melarsoprol gel. Trans. R. Soc. Trop. Med. Hyg. 89:1995;531-533.
18. Jennings F.W., Atouguia J.M., Murray M. Topical melarsoprol for trypanosomiasis. Lancet. 341:1993;1341-1342.
19. Jennings F.W., Atouguia J.M., Murray M. Topical chemotherapy for experimental murine African CNS-trypanosomiasis: the successful use of the arsenical, melarsoprol, combined with the 5-nitroimidazoles, fexinidazole or MK-436. Trop. Med. Int. Health. 1:1996;590-598.
20. Jennings F.W., Chauviere G., Viode C., Murray M. Topical chemotherapy for experimental African trypanosomiasis with cerebral involvement: the use of melarsoprol combined with the 5-nitroimidazole, megazol. Trop. Med. Int. Health. 1:1996;363-366.
21. Jennings F.W., Gray G.D. Relapsed parasitaemia following chemotherapy of chronic T. brucei infections in mice and its relation to cerebral trypanosomes. Contrib. Microbiol. Immunol. 7:1983;147-154.
22. Jennings F.W. Combination chemotherapy of CNS trypanosomiasis. Acta Trop. 54:1993;205-213.
23. Alfonso MO, Almeida APG, Atouguia JM, Costa J. Preliminary study of infection of Glossinia morsitans morsitans (Diptera, Glossinidae) with Trypanosoma brucei GVR 35 (Kinetoplastidae, Trypanosomatidae) in mice CD-1. XX International Congress of Entomology; Firenze, Italy. August 25-31 1996.
24. Zar J.H. Biostatistical analysis. 1996;Prentice Hall, New Jersey.
25. Jennings F.W. Suramin treatment of experimental Trypanosoma brucei infection of the central nervous system. Trans. R. Soc. Trop. Med. Hyg. 1995;89.
26. Keevil A.J. Subsequent histories of six cases of Trypanosoma rhodesiense infection treated with 'Bayer 205' or 'Fourneau 309'. Trans. R. Soc. Trop. Med. Hyg. 28:1934;101.